Cap-dependent endonuclease inhibitor (antiviral)
Baloxavir marboxil
Brand names: Xofluza
Adult dose
Dose: 40mg PO single dose (≥80kg: 80mg)
Route: Oral
Frequency: Single dose
Clinical pearls
- NICE NG34 / TA evaluation: alternative to oseltamivir for influenza A/B treatment within 48h
- UKHSA influenza guidance
- Single-dose convenience but resistance signal monitored
Contraindications
- Hypersensitivity
Side effects
- Diarrhoea
- Headache
- Hypersensitivity
- Bronchitis
- Sinusitis
Interactions
- Polyvalent cation products (separate by 2h)
Monitoring
- Symptom resolution
Reference: BNF; NICE NG34; UKHSA influenza; SmPC; https://bnf.nice.org.uk/drugs/baloxavir-marboxil/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023